Back

Loss of catalytic activity and impaired proteostasis in guanosine nucleotide-depleted LRRK2

Favetta, G.; Herbst, S.; Tombesi, G.; Iannotta, L.; Masato, A.; Battisti, I.; Tomkins, J. E.; Trabzuni, D.; Plotegher, N.; Gutierrez, M.; Arrigoni, G.; Manzoni, C.; Lewis, P. A.; Greggio, E.; Cogo, S.

2026-04-23 cell biology
10.64898/2026.04.21.719846 bioRxiv
Show abstract

Coding mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene represent the most common cause of familial Parkinsons disease (PD), and are frequently observed in idiopathic PD. In addition, variation around the LRRK2 locus has been shown to alter PD risk by genome-wide association studies. Disease-causing mutations cluster within the catalytic core of LRRK2 - composed of GTPase (ROC) and serine-threonine kinase domains - and lead to an increase in kinase activity, resulting in hyperphosphorylation of a subset of RAB GTPases and consequent cellular toxicity. However, the interplay between LRRK2s GTPase and kinase, and with the surrounding scaffold regions has remained underexplored, with implications for the prediction of on- and off-target effects associated with kinase inhibition. To address this gap, here we dissected the contributions of kinase, GTPase and scaffold domains to LRRK2 function in murine macrophages and tissues expressing endogenous levels of GTP/GDP-binding deficient Lrrk2 T1348N. Nucleotide-free Lrrk2 is devoid of both catalytic activities but maintains the scaffold shell, leading to significant reshaping of Lrrk2 interactome and engagement in novel interactions. This altered functional state leads to impaired autophagy and accumulation of enlarged lysosomes and autophagic cargo in macrophages and kidneys. Since pharmacological inhibition of LRRK2 is under clinical evaluation, our results reveal novel gain of scaffold functions upon loss of catalytic activity that warrant careful consideration.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Neurobiology of Disease
134 papers in training set
Top 0.3%
12.5%
2
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 7%
8.5%
3
Nature Communications
4913 papers in training set
Top 25%
7.3%
4
eLife
5422 papers in training set
Top 16%
4.9%
5
npj Parkinson's Disease
89 papers in training set
Top 0.5%
4.9%
6
Cell Reports
1338 papers in training set
Top 11%
4.4%
7
Journal of Cell Biology
333 papers in training set
Top 1%
2.6%
8
Cell Death & Disease
126 papers in training set
Top 0.6%
2.4%
9
Brain
154 papers in training set
Top 2%
2.1%
10
Science Advances
1098 papers in training set
Top 14%
1.9%
50% of probability mass above
11
Scientific Reports
3102 papers in training set
Top 57%
1.7%
12
International Journal of Molecular Sciences
453 papers in training set
Top 8%
1.7%
13
PLOS Genetics
756 papers in training set
Top 9%
1.7%
14
Journal of Biological Chemistry
641 papers in training set
Top 2%
1.7%
15
EMBO reports
136 papers in training set
Top 3%
1.5%
16
Neurobiology of Aging
95 papers in training set
Top 2%
1.3%
17
Communications Biology
886 papers in training set
Top 12%
1.3%
18
Nature Aging
51 papers in training set
Top 1%
1.3%
19
Advanced Science
249 papers in training set
Top 14%
1.2%
20
Life Science Alliance
263 papers in training set
Top 0.6%
1.2%
21
Molecular Neurodegeneration
49 papers in training set
Top 0.6%
1.2%
22
The EMBO Journal
267 papers in training set
Top 3%
1.1%
23
Developmental Cell
168 papers in training set
Top 10%
1.0%
24
Cell Chemical Biology
81 papers in training set
Top 3%
1.0%
25
Molecular Cell
308 papers in training set
Top 9%
1.0%
26
Stem Cell Reports
118 papers in training set
Top 0.8%
0.9%
27
Aging Cell
144 papers in training set
Top 3%
0.9%
28
iScience
1063 papers in training set
Top 26%
0.9%
29
PLOS Biology
408 papers in training set
Top 18%
0.8%
30
Science Translational Medicine
111 papers in training set
Top 6%
0.8%